Opendata, web and dolomites

AML-VACCiN SIGNED

Clinical development of a dendritic-cell vaccine therapy for acute myeloid leukaemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AML-VACCiN project word cloud

Explore the words cloud of the AML-VACCiN project. It provides you a very rough idea of what is the project "AML-VACCiN" about.

public    renowned    designated    inducing    cured    assemble    remission    conditional    treating    vaccine    companies    action    cell    mrd    approximately    private    off    biomarker    monitoring    enrolment    scientists    vaccin    stage    irdirc    forefront    ing    younger    line    adults    data    risk    iib    eradicate    unmet    shelf    personalised    safety    selective    dc    ultimately    patients    age    representing    acute    die    powerful    iia    vaccinate    children    001    disease    proof    immune    preclinical    medicinal    45    close    rare    treatment    orphan    profile    nine    intended    takes    relapse    medical    reduce    clinical    outcome    dendritic    standard    internationally    gt    status    85    dcp    minimal    approval    deadly    therapy    older    patient    innovative    toxic    shown    eradicating    consolidation    orchestrated    aml    institutes    immunotherapy    safe    efficacy    area    induction    residual    myeloid    leukaemia   

Project "AML-VACCiN" data sheet

The following table provides information about the project.

Coordinator
STICHTING VUMC 

Organization address
address: DE BOELELAAN 1117
city: AMSTERDAM
postcode: 1081 HV
website: www.vumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.amlvaccin.eu
 Total cost 8˙278˙716 €
 EC max contribution 6˙001˙482 € (72%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-two-stage
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VUMC NL (AMSTERDAM) coordinator 364˙640.00
2    BIONTECH INNOVATIVE MANUFACTURING SERVICES GMBH DE (IDAR OBERSTEIN) participant 2˙057˙500.00
3    IMMATICS BIOTECHNOLOGIES GMBH DE (TUEBINGEN) participant 1˙300˙650.00
4    LINICAL ACCELOVANCE EUROPE BV NL ('S-HERTOGENBOSCH) participant 1˙022˙313.00
5    DCPRIME BV NL (LEIDEN) participant 495˙150.00
6    UNIVERSITETET I BERGEN NO (BERGEN) participant 184˙989.00
7    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) participant 82˙320.00
8    HELSE BERGEN HF*HAUKELAND UNIVERSITY HOSPITAL NO (BERGEN) participant 82˙320.00
9    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) participant 82˙320.00
10    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 82˙320.00
11    UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ DE (Mainz) participant 82˙320.00
12    UNIVERSITATSKLINIKUM BONN DE (BONN) participant 82˙320.00
13    UPPSALA UNIVERSITET SE (UPPSALA) participant 82˙320.00
14    STICHTING VU NL (AMSTERDAM) participant 0.00

Map

 Project objective

Eradicating minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML) is an area of high unmet medical need. AML is a deadly rare disease that affects both children and adults. Approximately 45% of younger AML patients who are treated will be cured, and in older patients (>60 years of age), 85% will relapse and die within 2 years.

Immunotherapy has great potential for treating MRD and dendritic cell (DC) therapy is at the forefront of immunotherapy. The AML-VACCiN consortium takes this to the next level through clinical development of a highly-innovative DC vaccine - DCP-001 - that can be produced off-the-shelf and has a powerful preclinical and clinical profile. The aim is to vaccinate AML patients that have been brought into remission through standard induction or consolidation therapy, and to eradicate MRD and effectively reduce the risk of relapse.

In a clinical Phase I/IIa study, the DCP-001 vaccine has already shown to be safe, non-toxic and capable of inducing an AML-targeted immune response. DCP-001 is designated as an orphan medicinal product in the EU.

The AML-VACCiN consortium will advance the clinical development of the vaccine from early-stage (current status) towards proof of concept for safety and efficacy in a Phase IIb clinical study (intended outcome of this project). In addition, a biomarker program will be developed that enables more effective treatment monitoring, selective patient enrolment in future studies and ultimately personalised AML treatment. The deliverables resulting from this project can be used to assemble a data package to apply for conditional approval in Europe.

AML-VACCiN is the orchestrated action of three innovative companies and internationally renowned top medical scientists representing nine European medical institutes. In line with the IRDiRC objectives, this public-private consortium can bring a powerful AML-vaccine very close to clinical practice.

 Deliverables

List of deliverables.
Document providing the logo and templates for a uniform corporate look Other 2020-04-23 02:18:27
Communication and dissemination plan Documents, reports 2020-04-23 02:18:27

Take a look to the deliverables list in detail:  detailed list of AML-VACCiN deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Arjan A. van de Loosdrecht, Sandra van Wetering, Saskia J. A. M. Santegoets, Satwinder Kaur Singh, Corien M. Eeltink, Yvonne den Hartog, Malika Koppes, Jorn Kaspers, Gert J. Ossenkoppele, Ada M. Kruisbeek, Tanja D. de Gruijl
A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia
published pages: 1505-1518, ISSN: 0340-7004, DOI: 10.1007/s00262-018-2198-9
Cancer Immunology, Immunotherapy 67/10 2020-04-23

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AML-VACCIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AML-VACCIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

SBR (2020)

SMART BONE REGENERATION

Read More